



Corrigendum

Corrigendum to “Identification of an unknown trace-level impurity in bulk drug of Seroquel by high-performance liquid chromatography combined with mass spectrometry” [J. Pharm. Biomed. Anal. 44 (2007) 414–420]

Hui Xu^a, Danhua Wang^{a,b}, Cuirong Sun^a, Yuanjiang Pan^{a,*}, Minghua Zhou^{b,**}

^a Department of Chemistry, Zhejiang University, Hangzhou 310027, China

^b Zhejiang Huahai Pharmaceutical Co. Ltd., Linhai 317024, Taizhou, China

Available online 11 April 2008

The authors regret the misuse of the TM Seroquel. SeroquelTM is an exclusive product and a registered trademark for the AstraZeneca Group. The bulk drug referred to in this article has no connection to AstraZeneca's product SeroquelTM and has been manufactured independently by another company. The findings displayed in the article consequently bear no relevance to SeroquelTM.

DOI of original article: [10.1016/j.jpba.2007.03.002](https://doi.org/10.1016/j.jpba.2007.03.002).

* Corresponding author. Tel.: +86 571 87951264.

** Corresponding author.

E-mail address: panyuanjiang@zju.edu.cn (Y. Pan).